Sana Biotechnology

Yahoo Finance • 29 days ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the biop... Full story

Yahoo Finance • last month

Sana Biotechnology to Present at September 2025 Investor Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor... Full story

Yahoo Finance • last month

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 share... Full story

Yahoo Finance • 2 months ago

Sana Biotechnology prices $75 million public offering at $3.35 per share

SEATTLE - Sana Biotechnology, Inc. (NASDAQ:SANA), whose stock has surged over 160% year-to-date with a current market capitalization of approximately $959 million, has priced its underwritten public offering of 20,895,522 shares of common... Full story

Yahoo Finance • 2 months ago

Sana Biotechnology drops 13% on $75M stock issuance, prices at $3.35

* Sana Biotechnology (NASDAQ:SANA [https://seekingalpha.com/symbol/SANA]) priced [https://seekingalpha.com/pr/20192464-sana-biotechnology-announces-pricing-of-public-offering] its underwritten public offering of ~20.89M shares at $3.35 p... Full story

Yahoo Finance • 2 months ago

Sana Biotechnology Announces Pricing of Public Offering

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public off... Full story

Yahoo Finance • 2 months ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public o... Full story

Yahoo Finance • 2 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics, Inc. Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to... Full story

Yahoo Finance • 2 months ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Tran... Full story

Yahoo Finance • 2 months ago

Citi Maintained a Buy Rating on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Best American Penny Stocks to Buy According to Analysts.On July 2, Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) with a price target of... Full story

Yahoo Finance • 3 months ago

Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting

Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data... Full story

Yahoo Finance • 3 months ago

Morgan Stanley initiates Sana Biotechnology stock with Overweight rating

Investing.com - Morgan Stanley has initiated coverage on Sana Biotechnology (NASDAQ:SANA) with an Overweight rating and a $12.00 price target, joining a broader analyst consensus that sees significant upside potential. The stock, which h... Full story

Yahoo Finance • 3 months ago

Sana Biotechnology's SWOT analysis: promising cell therapy stock faces crowded market

Sana Biotechnology , Inc. (NASDAQ:SANA), a clinical-stage biotechnology company with a market capitalization of $645 million, has been making significant strides in the field of cell therapy. According to InvestingPro data, the stock has s... Full story

Yahoo Finance • 3 months ago

Citizens JMP reiterates Sana Biotechnology stock rating on diabetes data

Investing.com - Citizens JMP has reiterated its Market Outperform rating and $5.00 price target on Sana Biotechnology (NASDAQ:SANA) following updated clinical data from its diabetes treatment program. The biotechnology company presented... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Mixed in Afternoon Trading

Health care stocks were mixed Monday afternoon with the NYSE Health Care Index easing 0.3% and the H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Sana Biotechnology stock soars after positive diabetes treatment results

Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock surged 12.1% following the announcement of promising six-month follow-up results from a first-in-human study of its cell therapy for type 1 diabetes. The biotechnology company... Full story

Yahoo Finance • 3 months ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate that Sana’s Transplanted Pancreatic Isle... Full story

Yahoo Finance • 4 months ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing cl... Full story

Yahoo Finance • 4 months ago

Sana Biotechnology to Present at June 2025 Investor Conferences

SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor c... Full story

Yahoo Finance • 4 months ago

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana”... Full story